Replies to post #210857 on Biotech Values

[DewDiligence]

TNG.PA* starts phase-2 trial of TG4010 cancer vaccine in combination with Opdivo and chemotherapy in first-line, non-squamous NSCLC patients with low (or no) PD-L1 expression:

https://finance.yahoo.com/news/first-patient-dosed-phase-2-164500269.html

BMY is a co-sponsor of this single-arm trial, furnishing the Opdivo. The ct.g listing is at: https://clinicaltrials.gov/ct2/show/NCT03353675 .

*Since this trial was announced in Apr 2017, Transgene changed its ticker symbol from TRNG.PA to TNG.PA.